"Acid rain" eroded PPI "golden age", look at the "razole" family!

According to WHO data, the incidence rate of digestive system is 10% to 12%, and the incidence rate of digestive system in China is 11.2%, which is basically the same as that in many developed countries in Europe and America Ulcer, superficial gastritis and chronic atrophic gastritis are the most common diseases of digestive system Both gastric ulcer and duodenal ulcer are called peptic ulcer Its pathogenesis is the imbalance between the invasion of gastric acid and pepsin and the defense ability of mucosa Gastric acid produces self digestion on mucosa If the mucosal barrier is compared to the "roof", stomach acid and pepsin are compared to the "acid rain", the leakage of the "roof" may lead to the occurrence of peptic ulcer in case of small "acid rain" or excessive "acid rain" corroding the normal "roof" At present, proton pump inhibitor (PPI) is the most advanced drug in the treatment of peptic ulcer It can quickly cure ulcer by effectively and rapidly inhibiting gastric acid secretion and clearing up Helicobacter pylori PPI is the most widely used and the most effective drug in the treatment of acid related diseases in recent decades   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); Box sizing: border box! Im portant; word wrap: break word! Im portant; "> proton pump inhibitor became the first proton pump inhibitor omeprazole in the market, which was developed and listed by Astra in 1988 After omeprazole, several proton pump inhibitors such as lansoprazole, pantoprazole, esomeprazole and rabeprazole have been developed in the world In 2007, proton pump inhibitors reached the peak in foreign countries Under the imitation competition, the global market gradually entered a downhill period, while China's proton pump inhibitors market is still in a high-speed growth period In 2017, there were 12 prescription drugs for peptic ulcer and gastroesophageal reflux included in the national medical insurance drug catalogue, and proton pump inhibitors were the most numerous subtypes, respectively: the first generation of PPI drugs omeprazole, pantoprazole and lansoprazole; the second generation of PPI drugs esomeprazole (esomeprazole), eprazole and rabeprazole Among them, the new generation of PPI drugs have the characteristics of quick effect, long action time and small side effects, which is also the main reason for the rapid growth of its market According to the data of competition pattern of chemical drug terminals in public hospitals in key cities of mien, in 2016, the amount of proton pump inhibitor used in public hospitals in 16 key cities in China reached 4.5 billion yuan, an increase of 6% over the previous year, showing a continuous growth trend Proton pump inhibitors have stronger acid inhibition than H2 receptor blockers, and they are the most popular products in the market in recent years China has approved the listing of proton pump generic drugs by many pharmaceutical companies, which has improved the product structure and intensified market competition The newly approved pharmaceutical manufacturers challenge the manufacturers who have been operating for many years with new products, new processes and new dosage forms none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> lansoprazole leads the PPI market According to the data of chemical terminal competition pattern of public hospitals in key cities of mienei.com, in 2016, lansoprazole ranked first in the PPI market of public hospitals in 16 key cities in China, with a sales volume of 1.239 billion yuan, an increase of 5.52% year-on-year It was shortlisted as the top 10 public hospitals in key cities, accounting for 8.34% of the share Lansoprazole was first developed and listed by Takeda, Japan, under the trade name of dakopuron In 2008, Jiangsu aosaikang Pharmaceutical Co., Ltd developed and marketed lansoprazole powder for injection, which gradually changed the market of lansoprazole So far, CFDA has approved 70 pharmaceutical manufacturers to hold the production approval of lansoprazole Lansoprazole is a new drug to inhibit the secretion of gastric acid Its antibacterial activity against Helicobacter pylori is 4 times higher than that of omeprazole Its bioavailability is higher than that of the same species, the incidence of adverse reactions and low lipophilicity are stronger Lansoprazole has a significant healing and promoting effect on chronic ulcers in the middle-aged and the elderly, and ulcers that are difficult to be cured by receptor antagonists In 2016, domestic lansoprazole drugs in public hospitals in key cities accounted for 96% of the market share, while the original imported drug daclopram accounted for 4% of the market share Among the top five manufacturers in terms of sales volume, Jiangsu aosaikang, Shandong Luoxin, Beijing yuekang, Changzhou siyao and Wutian accounted for 30.60%, 25.52%, 13.46%, 10.28% and 4.01% respectively According to the data of competition pattern of chemical drug terminals in public hospitals in key cities of mienei.com, powder injection accounts for 89.62%, capsule 5.44% and tablet 4.94%       none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> eprazole is listed in the national medical insurance catalogue in 2017 It is the first and only innovative drug in the field of digestion and treatment in China It is developed and listed by Lizhu group On December 11, 2007, alprazole obtained the new drug certificate and production approval issued by the State Food and drug administration, and was first listed in China in 2008; it obtained 37 invention patents and 23 patent authorizations in the United States and Europe Iprazole is an irreversible proton pump inhibitor of benzimidazole After oral administration, the drug selectively enters the gastric parietal cells and transforms into the active metabolite of subsulfonamide to play a therapeutic role It has the advantages of significantly improving the acid inhibition time of similar drugs, large individual differences and multiple drug interactions In addition, it used the key technologies of API oxidation and crystallization and targeted drug release technology in manufacturing, overcome the difficulties in the process of R & D and industrialization, and won the second prize of national science and Technology Progress Award in 2015 According to the competition pattern of chemical terminal of public hospitals in key cities of mienei.com, in 2016, the sales volume of eprazole in public hospitals in 16 key cities in China was 85.18 million yuan, an increase of 49.47% year on year In the first half of 2017, the sales volume of domestic alprazole reached 209 million yuan, a year-on-year increase of 46.77% With the introduction of the new medical insurance catalogue of more than 20 provinces, cities and autonomous regions in China, in 2017, the sales volume of alprazole exceeded 500 million yuan, which was a solid success none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); Box sizing: border box! Im assistant; word wrap: break word! Im assistant; "> rabeprazole has a growth rate of 44.53% Rabeprazole belongs to the second generation of new proton pump inhibitors On August 19, 1999, the US FDA approved rabeprazole of Weicai company to be listed on the market under the trade name of pariet, which is applicable to the treatment of corrosive gastroesophageal reflux disease and maintenance treatment after recovery, as well as the treatment of duodenal ulcer and zosenger Ellison syndrome Rabeprazole is a reversible proton pump inhibitor with high pkaA value In vitro, its anti secretory activity is 2-10 times stronger than omeprazole Oral rabeprazole can activate rapidly in vivo and play an acid inhibiting role in combination with proton pump Rabeprazole entered the Chinese market in February 2000 under the trade name of polit According to the competition pattern of chemical terminal of public hospitals in key cities of mienei.com, the sales volume of rabeprazole in 16 key cities in 2016 was RMB 625 million, an increase of 44.53% year on year The market shares of the top 5 manufacturers are 21.6% of Weicai (China) polite enteric coated tablets, 18.51% of Jinuo enteric coated capsules in Jichuan, Jiangsu, 17.01% of aoboping powder injection in Changao, Nanjing, 10.81% of ansfi enteric coated tablets in Dikang, Chengdu, and 10.66% of raport enteric coated tablets in hausen, Jiangsu It is worth mentioning that from the analysis of the registration approval and competition pattern of rabeprazole preparations, the proportion of the top 5 manufacturers in rabeprazole market is relatively reasonable Under the situation of the first choice of oral preparations in the 2017 national medical insurance catalog, rabeprazole will become one of the varieties with good market prospects in the next two years.